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Abstract
Medium-chain acyl-coA dehydrogenase deficiency (MCADD) is 
an autosomal recessive disorder of fatty acid β- oxidation, which 
is inherited in an autosomal recessive manner. The enzyme plays a 
role in hepatic Ketogenesis, which is a significant source of energy 
during prolonged fasting. There is no metabolic screening program 
except for phenylketonuria (PKU) and hypothyroidism in Iran, and 
such screening is exclusively implemented in the case of babies with 
unprovoked seizures and hypoglycemia and previous unexplained 
sibling deaths. In this paper, we report a case of a seven-year-old boy 
who presented with afebrile serial seizures leading to coma and death. 
in this regard, metabolic screening tests were used to determine the 
exact cause of encephalopathy and the final diagnosis.
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Medium-chainacyl-coA dehydrogenase deficiency (MCADD) is 
an autosomal recessive inborn error of mitochondrial fatty acid 
β-oxidation (1). It is also the most common inherited disorder of 
mitochondrial fatty acid oxidation. The early detection of MCADD 
in neonatal screening programs provide such patients with better 
outcomes as the parents receive some instructions to avoid prolonged 
fasting and use high carbohydrate content dishes during intercurrent 
illnesses (7).
There have been about 20 case reports in Asia (2). In Iran, because 
of the lack of a routine metabolic screening program, the samples 
are delivered to a laboratory in Germany in the case of high clinical 
suspicion. Herein we describe a seven-year-old boy, who suddenly 
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developed serial afebrile seizures with no history 
of developmental delay and previous seizures. The 
seizures were followed by the loss of consciousness 
and finally lead to death in two days.
Considering the death of his older sibling with 
similar clinical presentation and detecting 
hypoglycemia without ketosis in the urine sample, 
we took dry blood spot samples for tandem mass 
spectrometry. The results sent by the lab confirmed 
the MCADD diagnosis. Introducing neonatal 
metabolic screening programs may contribute to 
avoiding similar scenarios.
Case Report
The patient was a 7-year old boy from Miandoab, a 
city in the south of West Azarbaijan province, Iran. 
He exhibited no history of prenatal and postnatal 
diseases and had a normal growth. His healthy 
parents were cousins. He had successfully passed 
the first grade of the primary school. The patient 
suddenly experienced febrile serial generalized 
tonic-clonic seizures and the hospitalized in Shahid 
Abbasi teaching Hospital in Miandoab.
After controlling his seizures using the bolus doses 
of phenobarbital and phenytoin, his consciousness 
level decreased, thereby necessitating endotracheal 
intubation and assisted ventilation. Then the patient 
was transferred to our tertiary subspecialty ward in 
Urmia’s Motahari Hospital. When we visited the 
patient for the first time, he was suffering from a 
deep coma; however, his vital signs were normal.
On physical examinations, his pupils were dilated 
with inadequate response to light, the liver was 
palpable about 4cm below the costal margin; his 
muscular tone severely diminished, and deep 
tendon reflexes were undetectable. His examination 
was otherwise normal.
Routine laboratory tests revealed a nonketotic 
hypoglycemia (Table 1) and elevated liver 
enzymes (Table 2). According to the endocrinology 
consultation, a blood and urine sample was 
obtained to further evaluation into the exact cause 
of hypoglycemia. The obtained results ruled out 
ethiologies such as lipid malabsorbtion (TG=92 
mg/dl¸ cholesterol 73 mg/dl¸ LDL=37 mg/dl; 
disorder of respiratory chain (lactate =13 ng/
dl)¸ adrenal insufficiency (cortisol=62.4µg/dl)¸ 
hypopituitarism (ACTH=411 pg/ml), and hyper 
insulinemia (insulin= 0.7µIU/ml)[Figure 3].
Laboratory tests suggested by our pediatric 
gastroenterologist to detect the viral or immune 
cause of hepatitis revealed nothing, and the 
urine toxicology screening test was negative. 
Since his older male sibling died five years ago 
with the similar symptoms, the inherited inborn 
errors of metabolism were highly likely; thus, 
we delivered dried blood spot samples to a lab in 
Germany for tandem mass spectrometry. The brain 
computerized tomography revealed no edema. 
Unfortunately, the patient died two days after 
admission due to multiple organ system failures. 
The acylcarnitine analysis showed significantly 
elevated levels of medium-chain acylcarnitines 
(hexanoylcarnitine(c6)1.3µmol/lit (0- 0.15) and 
octanoylcarnitine(c8)0.73 µmol/lit (0- 0.23), 
which is compatible with medium-chain acyl-coA 
dehydrogenase deficiency (Table 4).
The filter paper screening also revealed no 
indication of congenital hypothyroidism ¸ adrenal 
hyperplasia¸ galactosemia ¸biotinidase deficiency¸ 
amino acid metabolism disorders and tyrosinemia 
typ1. Molecular genetics verification was 
impossible due to the patient’s death.
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Table 1. Biochemistry 
TEST Result Unit Reference value
BUN 37 Mg/dl 7-20
Creatinin 0.6 Mg/dl 0.5-1.3
AST 234(H) u/L 5-40
ALT 86(H) u/L 5-40
ALKL-P 371 Iu/L 180-1200
Blood sugar <20 Mg/dl
Serum Na 136 MEq/l 135-148
Serum K 5.1 MEq/l 3.5-5
Serum Ca 8.3 Mg/dl 8.6-10
CRP 19 <10 negative
>10 positive
WBC 37 Mg/dl 7-20
Hb 0.6 Mg/dl 0.5-1.3
HCT 234(H) u/L 5-40
PLT 86(H) u/L 5-40
ESR 371 Iu/L 180-1200
BUN 37 Mg/dl 7-20
Creatinin 0.6 Mg/dl 0.5-1.3
AST 234(H) u/L 5-40
ALT 86(H) u/L 5-40
ALKL-P 371 Iu/L 180-1200
Blood sugar <20 Mg/dl
Serum Na 136 MEq/l 135-148
Serum K 5.1 MEq/l 3.5-5
Serum Ca 8.3 Mg/dl 8.6-10
CRP 19 <10 negative
>10 positive
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Table 2. Biochemistry 
TEST Result Unit Reference value
Ceruloplasmin 0.230 g/d 0.15-0.30
LKM 1.6 IU/ML <20 negative
>20 positive




CPK 19257 (H) Iu/L 20-190
LDH 2550 (H) Iu/L 200-450
Table 3. Biochemistry & Hormones
TEST Result Unit Reference value
Uric acid 14.9 mg/dl 3-7
Cholesterol 73 mg/dl normal<200
Triglyceride 92 Mg/dl normal<200
HDL 22 Mg/dl 30-80
Lactate 13 Mg/dl Normal 4.5-20 Mg/dl
Ammoniac 187 Mg/dl 19-90
T3 35 Ng/dl 76.3-220
TSH 0.14 Miu/ml 0.30-5.60
Cortisol 62.4 Microgram/dl Child 3.0-21.0
Insulin 0.7 Miu/ml 3.21-16.3
ACTH 411 Pg/ml 1.4-106
Table 4. Acyl carnitine analysis 
Result Reference Range
Hexanoylcarnitine(c6) 1.03µmol/lit <0.40 µmol/lit
Octanoyl carnitine(c8) 0.73 µmol/lit <0.20 µmol/lit
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Result Reference Range
Decanoyl carnitine(c10) 0.26 µmol/lit <0.40 µmol/lit
Decenoyl carnitine(c10:1) 0.69 µmol/lit <0.20 µmol/lit
Acyl carnitine analysis showed significantly elevated levels of Medium-chain acylcarnitines; hence, 
Medium-chain acyl-coA dehydrogenase deficiency (MCADD) must be suspected.
Discussion
Medium-chainacyl-coA dehydrogenase is a 
mitochondrial enzyme catalyzing the 
dehydrogenation of acyl coA with a chain length 
of 4-12 carbon atoms.
 Lack of the MCAD enzyme makes glycine, 
carnitine esters, and dicarboxylic acids accumulate 
within the body, thereby arousing specific disease 
presentation with hypoglycemia, vomiting, and 
encephalopathy during an intercurrent illness 
or prolonged fasting (1-4). Hepatomegaly and 
liver damage are often associated with rapid 
development of coma and death; hence, 16% of the 
survived cases would suffer from severe neurologic 
deficits (4,5). The acylcarnitine profile of patients 
with MCADD is characterized by a high level of 
C6-C10 species, especially octanoylcarnitine (1, 3, 
4, 6).
Although there is a metabolic screen test for the 
diagnosis and screening of patients with MCADD, 
given the likelihood of the diseases reoccurrence 
in subsequent children, adopting some measures 
seems necessary to prevent the recurrence of the 
same diseases and make a diagnosis before birth 
by using genetic evaluation and detecting gene 
mutation as Homozygote and Heterozygote for the 
985A>G (4, 7, 8, 9).
This patient presented with status epilepticus, 
coma, hepatomegaly, and impaired liver function 
tests died in a few days.  To sum up, we faced a 
patient suffering from hepatic encephalopathy, 
and differential diagnosis included viral, 
immune, toxicologic, and metabolic factors. Our 
investigation of hepatotropic and non-hepatotropic 
viruses revealed nothing; however,  the toxicology 
screening tests and immunologic assessments 
introduced metabolic causes as the main factor, 
given the history of his older sibling’s death with 
similar clinical presentations. Accordingly, we 
performed a metabolic screening test to rule out 
respiratory chain disorders, tyrosinemia type 1, 
Hashimoto encephalopathy, galactosemia, the 
metabolism disorders of amino acids, and fatty acid 
oxidation chain disorders. Acylcarnitine analysis 
showed significantly-elevated levels of medium-
chain acylcarnitines (C6_C10 species), indicating 
the MCAD deficiency as the cause of hepatic 
encephalopathy. We failed to justify the diagnosis 
based on molecular genetic testing because of the 
death of the patient (7,10).
A metabolic screening program might contribute 
to the early detection and treatment of metabolic 
disorders (8, 11). Similarly, molecular genetic 
testing would facilitate providing prenatal 
diagnosis and treatment as well as reproductive 
counseling to the involved families.
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